甲状腺髓样癌:单一机构30年经验及复发危险因素
该回顾性研究分析了1990至2023年单中心68例接受手术的甲状腺髓样癌患者,复发率为22%,中位随访4.7年。男性、侧颈淋巴结阳性及高/最高风险RET突变与复发显著相关,术前降钙素>2175 pg/mL提示远处转移,手术范围与复发无显著关联。
要点
- 男性、侧颈淋巴结阳性、高/最高风险RET突变与复发显著相关。
- 术前降钙素>2175 pg/mL是远处转移的强预测指标(AUC 0.893)。
- 手术范围与复发无显著关联(P = .634)。
核心结论
- 约四分之一接受手术的甲状腺髓样癌患者会复发。
- 与复发相关的危险因素为男性、侧颈淋巴结转移及高/最高风险水平RET突变,而不一定是手术类型。
- 术前降钙素>2175 pg/mL提示晚期疾病,应促使进一步评估。
研究设计与样本
- 回顾性病历审查,1990年至2023年在单一专科三级转诊中心进行。
- 纳入68例接受手术的甲状腺髓样癌患者,采用描述性分析和回归模型。
主要发现
- 诊断时平均年龄54.9岁(42.2-64.1),女性占65%(n = 44)。
- 淋巴结转移和远处转移分别占24%(n = 16)和4%(n = 3)。
- RET突变存在于52%(n = 35)的患者中:最高风险6%,高风险7%,中风险39%。
- 平均肿瘤大小1.9 cm(1.2-3.2),术前平均降钙素504.4 pg/mL(133.2-1833.8)。
- 全甲状腺切除术10例,全甲状腺切除+中央颈淋巴结清扫28例,全甲状腺切除+中央及侧颈淋巴结清扫25例;最终病理中央淋巴结阳性40%,侧颈淋巴结阳性25%;复发率22%,中位随访4.7年(1.2-28.0)。
关键数值与推荐
- 男性与复发显著相关(HR 5.81,P = .021)。
- 侧颈淋巴结阳性与复发显著相关(HR 8.10,P = .011)。
- 高/最高风险水平RET突变与复发显著相关(HR 8.66,P = .004)。
- 术前降钙素>2175 pg/mL对远处转移有强预测价值(AUC 0.893),对侧颈病变有较好预测价值(AUC 0.706)。
- 手术范围与复发无显著关联(P = .634)。
临床怎么用
- 对于甲状腺髓样癌术后患者,男性、侧颈淋巴结转移及高/最高风险RET突变者需关注复发风险。
- 术前降钙素>2175 pg/mL提示晚期疾病,应促使进一步评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Medullary thyroid cancer (MTC) has a historic recurrence rate up to 50%, and surgery remains the only cure. OBJECTIVE: This study aims to assess factors related to recurrence and metastatic spread in MTC. METHODS: Retrospective chart review was performed from 1990 to 2023 at a single specialized tertiary care referral center. Descriptive analysis and regression models were used for analysis. Sixty-eight patients with MTC, who underwent surgery, were included and the main outcome measure was recurrence. RESULTS: Mean age at diagnosis was 54.9 years (42.2-64.1), 65% (n = 44) females. Lymph node and distant metastases were found in 24% (n = 16) and 4% (n = 3), respectively. RET mutations were present in 52% (n = 35): MTC risk levels were highest 6%, high 7%, and moderate 39%. Mean tumor size was 1.9 cm (1.2-3.2) and mean preoperative calcitonin was 504.4 pg/mL (133.2-1833.8). Total thyroidectomy (TT) was performed in 10 patients, TT + central neck dissection (CND) in 28, and TT + CND + lateral neck dissection (LND) in 25. On final pathology, 40% had positive central nodes and 25% had positive lateral nodes. Recurrence was 22%, median follow-up 4.7 years (1.2-28.0). Male gender (hazard ratio [HR] 5.81, P = .021), positive lateral neck nodes (HR 8.10, P = .011), and high/highest MTC risk level RET mutations (HR 8.66, P = .004) were significantly associated with recurrence. Preoperative calcitonin >2175 pg/mL was a strong predictor for distant metastasis (area under the curve [AUC] 0.893) and a good predictor for lateral neck disease (AUC 0.706). Extent of surgery was not significantly associated with recurrence (P = .634). CONCLUSION: One of 4 patients undergoing surgery for MTC will recur. Risk factors associated with recurrence are male gender, lateral lymph node metastasis, and high/highest MTC risk level mutations, but not necessarily surgery type. Preoperative calcitonin >2175 pg/mL is suggestive of advanced disease and should prompt further evaluation.
引用
- Abou Azar S, Tobias J, Applewhite M, et al. Medullary Thyroid Cancer: Single Institute Experience Over 3 Decades and Risk Factors for Recurrence. J Clin Endocrinol Metab. 2024. PMID: 38651609. doi:10.1210/clinem/dgae279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。